C1 Esterase Inhibitor Market Size, Share & Industry Analysis, By Product (Berinert, Cinryze, Haegarda, Ruconest, and Others), By Sources (Plasma Derived and Recombinant), By Age Group (Adult, Pediatric, and Adolescent) Route of Administration (Intravenous and Subcutaneous), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global C1 esterase inhibitor market size was valued at USD 1.30 billion in 2024 and is projected to reach USD 1.73 billion by 2032, exhibiting a CAGR of 3.6% during the forecast period. C1 esterase inhibitors are used for the treatment of rare diseases, with a primary focus on hereditary angioedema (HAE). These inhibitors comprise a vital plasma protein that replaces deficient or dysfunctional C1-inhibitor proteins.

The market is expected to grow significantly during the forecast period. Furthermore, the rising prevalence of hereditary angioedema, product approvals, and awareness programs are expected to boost market growth.

·         For instance, in April 2020, Pharming received European Commission approval for RUCONEST for the treatment of acute hereditary angioedema attacks in children.

C1 Esterase Inhibitor Market Driver

Rising Attacks Associated with Hereditary Angioedema to Increase the Market Demand

One of the prominent factors driving market growth is the rising number of cases of hereditary angioedema within the total angioedema population. This condition leads to recurrent episodes of severe swelling in various parts of the body, including the skin, mucous membranes, and internal organs. Such conditions require immediate action to increase C1 esterase inhibitor in the body, thereby stopping excessive inflammation and tissue damage.

• For instance, in June 2022, as per the Rare Disease Advisory, hereditary angioedema affects 1 in 50,000 people globally, with prevalence ranging from 1:10,000 to 1:150,000.

Download Free sample to learn more about this report.

According to the Rare Disease Advisory report, the prevalence of HAE in Norway and Spain is estimated to be 1.75 and 1.09 patients per million population, respectively.

C1 Esterase Inhibitor Market Restraint

Launch of Plasma-Kallikrein Inhibitors to Hamper the Market Growth

The development and approval of plasma-kallikrein inhibitors for the treatment of hereditary angioedema (either as monotherapy or in combination) may restrict the growth of the C1 esterase inhibitor market. These inhibitors can potentially reduce the reliance on C1-INH products, leading to increased competition in the market.

• For instance, in February 2025, Takeda Pharmaceutical Company Limited announced that the EMA had approved a 2 mL pre-filled pen option for TAKHZYRO (lanadelumab), a human monoclonal antibody plasma kallikrein inhibitor for the treatment of adolescents and adult patients with hereditary angioedema. Such launches are expected to decrease the product demand, hindering market growth.

C1 Esterase Inhibitor Market Opportunity

Expansion of Home-Based Administration Programs to Offer Lucrative Growth Opportunity

The expansion of home-based administration programs for C1 esterase inhibitor therapies presents a significant growth opportunity within the market. The shift toward home-based care reduces healthcare costs and minimizes hospital visits, making it an attractive option for healthcare providers and payers. The companies’ focus on offering self-administration programs and user-friendly delivery methods to enhance convenience, adherence, and quality of life is likely to offer new opportunities for market expansion.

• For instance, CSL has launched HAEGARDA Connect to assist with preparing and administering medicines at home. Such programs boost product adoption and cater to the market growth.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Key Diseases, By Key Countries/ Regions, 2024
• Key Industry Developments (Mergers, Acquisitions, Collaborations, and Others)
• Pipeline Analysis
• Regulatory & Reimbursement Scenario, By Key Countries/ Regions

Analysis by Product

Based on product, the market is categorized into Berinert, Cinryze, Haegarda, Ruconest, and others.

The Berinert segment dominated the market. The dominant share of the segment is attributed to the development and approval of a new kit for patient convenience.

• For instance, in August 2021, CSL received approval from the U.S. FDA for the BERINERT IV kit for the treatment of HEA, increasing patient convenience.

Analysis by Source

By source, the market is subdivided into plasma derived and recombinant.

The plasma-derived segment held a significant share of the market. This is due to the presence of major C1 Esterase inhibitors derived from plasma. Additionally, increasing approval of plasma-derived products is expected to bolster the segment’s growth.

• For instance, in April 2021, CSL announced the approval of HAEGARDA, a human plasma-derived C1 esterase inhibitor, from Health Canada.

Analysis by Age Group

The market, on the basis of age group, is subdivided into adult, pediatric, and adolescent.

The pediatric segment is expected to experience exponential growth during the forecast period. The segment is anticipated to expand owing to increasing product approvals for pediatrics.

• For example, in September 2020, CSL announced that HAEGARDA had been approved by the U.S. Food and Drug Administration (FDA) for the treatment of HAE attacks in patients aged 6 years and older.

Analysis by Route of Administration

The market has been studied across intravenous and subcutaneous considering the route of administration.

The subcutaneous segment held a significant market share. The segment’s growth is attributed to the increased focus on home care and patient convenience for self-administration. Additionally, the launches and approvals of subcutaneous products are expected to propel the segment’s growth.

• For example, in September 2022, CSL announced that the Ministry of Health, Labour and Welfare of Japan had approved Berinert S.C. Injection 2000 for subcutaneous (SC) injection to prevent acute hereditary angioedema.

Analysis by Distribution Channel

Based on the distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies.

The drugstore and retail pharmacies segment held the largest market share. These channels are increasingly focusing on raising awareness to propel the segment’s growth.

• For instance, in May 2021, Optime Care, a renowned pharmacy and patient management organization, celebrated the 10th anniversary of its hereditary angioedema (HAE) awareness campaign. This campaign aimed to increase understanding of the disease among the general public, healthcare professionals, decision-makers, and industry representatives.

Regional Analysis

Request for Customization   to gain extensive market insights.

On the basis of geography, the market has been studied across five regions, covering Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a dominant share of the global C1 esterase inhibitor market in 2024, accounting for 49%. The rising prevalence of HEA, combined with the presence of key players in the market offering advanced products and strong regulatory support, is expected to propel market growth in the region.

• For instance, according to the Rare Disease Advisory, in the U.S., HAE episodes result in 15,000 to 30,000 annual emergency department admissions. Such a large number of hospital admissions increases the demand for adequate treatment options.

The Europe market holds a considerable market share. The increasing number of approvals and the presence of awareness programs for HAE are expected to propel the regional market growth.

• For instance, according to HAEi.org, in May 2025, an annual patient meeting was held in Zurich, Switzerland, with HAE experts sharing valuable insights, information, and practical tips for everyday life with people suffering from HAE.

Moreover, the Asia Pacific is expected to grow at a significant CAGR during the forecast period. The increasing incidence of HEA and the growing presence of advanced treatment products are expected to drive market growth in the Asia Pacific region.

Key Players Covered

The global C1 Esterase Inhibitor market is highly consolidated, with few major standalone providers.

The report includes the profiles of the following key players:

• CSL (Australia)
• Takeda Pharmaceutical Company Limited (Japan)
• Pharming Healthcare, Inc.  (U.S.)
• Ractigen Therapeutics (China)
• Octapharma AG (Switzerland)

Key Industry Developments

• December 2022: Takeda Pharmaceutical Company Limited launched Cinryze in India.
• July 2021: Orchard Therapeutics and Pharming Group N.V. collaborated to develop and commercialize OTL-105, aiming to increase the C1 esterase inhibitor for the treatment of hereditary angioedema.